NCT02973048View on ClinicalTrials.gov

Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

November 8, 2018

Study Completion Date

November 8, 2018

Conditions
Pregnant WomenPainHypotension
Interventions
DRUG

Hyperbaric bupivacaine

The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.

DRUG

Hyperbaric prilocaine

The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.

Trial Locations (2)

1000

University Hospital Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels

1070

Clinique Ste-Anne/St-Remi, Anderlecht

All Listed Sponsors
lead

Centre Hospitalier Universitaire Saint Pierre

OTHER

NCT02973048 - Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia | Biotech Hunter | Biotech Hunter